These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 34404077)

  • 21. Grade 4 epistaxis in a woman with metastatic breast cancer treated with bevacizumab: a case report.
    Yanagihara K; Takei H; Iida S; Yamashita K; Kurita T; Iwamoto M; Saegusa H; Uchida E
    J Nippon Med Sch; 2014; 81(5):333-6. PubMed ID: 25391703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Paclitaxel plus Bevacizumab Combination Therapy for Esophageal Metastasis of Breast Cancer-A Case Report].
    Kawai H; Ishimaru R; Miyauchi S; Morihiro T; Kurosaki T; Yoshida R; Uno F; Yamashita K; Ishizaki M
    Gan To Kagaku Ryoho; 2023 Dec; 50(13):1730-1732. PubMed ID: 38303188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [A Case of Locally Advanced and Metastatic Breast Cancer Treated with Preoperative Bevacizumab Combination Chemotherapy That Attained Local Control].
    Watanabe N; Furukawa J; Minoji T; Tamai K; Kitahara T; Yamamura N; Okamura S; Fukuchi N; Ebisui C; Yokouchi H; Kinuta M
    Gan To Kagaku Ryoho; 2018 Jul; 45(7):1097-1099. PubMed ID: 30042280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Axillary Arterial Bleeding with Administration of Bevacizumab plus Paclitaxel in a Patient with Recurrent Breast Cancer-A Case Report].
    Tsuruda Y; Masuda T; Hayashi N; Noda M; Otsu H; Kuroda Y; Eguchi H; Tanaka F; Natsugoe S; Mimori K
    Gan To Kagaku Ryoho; 2020 Jan; 47(1):117-119. PubMed ID: 32381877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.
    de Gramont A; Van Cutsem E
    Oncology; 2005; 69 Suppl 3():46-56. PubMed ID: 16301835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
    Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
    J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study.
    Dieras V; Pop S; Berger F; Dujaric ME; Beuzeboc P; Escalup L; Bidard FC; Cottu PH; LE Tourneau C; Piperno-Neumann S; Laurence V; Robain M; Asselain B; Pierga JY
    Anticancer Res; 2017 Mar; 37(3):1403-1407. PubMed ID: 28314310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A Case of Triple Negative Breast Cancer with Left Buttock Metastasis].
    Abe A; Nishimura A; Okano K; Suzuki T; Hakamada K
    Gan To Kagaku Ryoho; 2023 Dec; 50(13):1624-1626. PubMed ID: 38303362
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.
    Lam SW; de Groot SM; Honkoop AH; Jager A; ten Tije AJ; Bos MM; Linn SC; van den Bosch J; Kroep JR; Braun JJ; van Tinteren H; Boven E;
    Eur J Cancer; 2014 Dec; 50(18):3077-88. PubMed ID: 25459393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.
    Rochlitz C; Bigler M; von Moos R; Bernhard J; Matter-Walstra K; Wicki A; Zaman K; Anchisi S; Küng M; Na KJ; Bärtschi D; Borner M; Rordorf T; Rauch D; Müller A; Ruhstaller T; Vetter M; Trojan A; Hasler-Strub U; Cathomas R; Winterhalder R;
    BMC Cancer; 2016 Oct; 16(1):780. PubMed ID: 27724870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A Case of Male Recurrent Breast Cancer Successfully Treated with Bevacizumab plus Paclitaxel Therapy for Carcinomatous Pericarditis].
    Nara M; Oshino T; Hagio K; Takazaki E; Yamashita H
    Gan To Kagaku Ryoho; 2020 Jul; 47(7):1085-1087. PubMed ID: 32668857
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
    von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J
    Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Patient with Recurrent Breast Cancer Who Developed Radiation Esophagitis with Severe Esophageal Stenosis after Combined Bevacizumab and Paclitaxel Therapy-A Case Report].
    Matsuura K; Osaki A; Ichinose Y; Fujimoto A; Nukui A; Saeki T
    Gan To Kagaku Ryoho; 2020 Nov; 47(11):1605-1608. PubMed ID: 33268737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Bevacizumab plus Paclitaxel Therapy Was Effective for Metastatic Breast Cancer with Dysphagia Due to Mediastinal Lymph Node Metastasis-A Case Report].
    Kodera A; Inoue H; Ogura K; Sakaguchi S; Yukawa H; Matsuoka A; Tanaka N; Kinoshita J; Yoshimatsu K; Naritaka Y; Hirano A
    Gan To Kagaku Ryoho; 2018 Dec; 45(13):2276-2278. PubMed ID: 30692436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.
    Smith IE; Pierga JY; Biganzoli L; Cortés-Funes H; Thomssen C; Pivot X; Fabi A; Xu B; Stroyakovskiy D; Franke FA; Kaufman B; Mainwaring P; Pienkowski T; De Valk B; Kwong A; González-Trujillo JL; Koza I; Petrakova K; Pereira D; Pritchard KI;
    Ann Oncol; 2011 Mar; 22(3):595-602. PubMed ID: 20819780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical Efficacy of Paclitaxel plus Bevacizumab Combination Therapy for Bone Marrow Carcinomatosis Arising from Breast Cancer - A Case Report].
    Nakayama I
    Gan To Kagaku Ryoho; 2017 Nov; 44(12):1391-1392. PubMed ID: 29394644
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.
    Lang I; Inbar MJ; Kahán Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Messinger D; Brodowicz T; Zielinski C
    Eur J Cancer; 2012 Nov; 48(17):3140-9. PubMed ID: 22640829
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030).
    Grau JF; Farinas-Madrid L; Oaknin A
    Int J Gynecol Cancer; 2020 Jan; 30(1):139-143. PubMed ID: 31645423
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer.
    Mayer EL; Dhakil S; Patel T; Sundaram S; Fabian C; Kozloff M; Qamar R; Volterra F; Parmar H; Samant M; Burstein HJ
    Ann Oncol; 2010 Dec; 21(12):2370-2376. PubMed ID: 20497961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Paclitaxel plus Bevacizumab Therapy plus Surgical Resection Results in Local Control of Stage ⅢC Breast Cancer].
    Tanaka M; Ono S; Nohara Y; Yoshinaga Y; Sato T; Yamashita S; Morita A; Takagi S
    Gan To Kagaku Ryoho; 2021 Nov; 48(11):1393-1395. PubMed ID: 34795133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.